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Abstract
Background: Little is known on the effectiveness of influenza vaccine in ESRD patients. This study compared the incidence
of hospitalization, morbidity, and mortality in end-stage renal disease (ESRD) patients undergoing hemodialysis (HD)
between cohorts with and without influenza vaccination.
Methods: We used the insurance claims data from 1998 to 2009 in Taiwan to determine the incidence of these events
within one year after influenza vaccination in the vaccine (N= 831) and the non-vaccine (N = 3187) cohorts. The vaccine
cohort to the non-vaccine cohort incidence rate ratio and hazard ratio (HR) of morbidities and mortality were measured.
Results: The age-specific analysis showed that the elderly in the vaccine cohort had lower hospitalization rate (100.8 vs.
133.9 per 100 person-years), contributing to an overall HR of 0.81 (95% confidence interval (CI) 0.72–0.90). The vaccine
cohort also had an adjusted HR of 0.85 [95% CI 0.75–0.96] for heart disease. The corresponding incidence of pneumonia and
influenza was 22.4 versus 17.2 per 100 person-years, but with an adjusted HR of 0.80 (95% CI 0.64–1.02). The vaccine cohort
had lowered risks than the non-vaccine cohort for intensive care unit (ICU) admission (adjusted HR 0.20, 95% CI 0.12–0.33)
and mortality (adjusted HR 0.50, 95% CI 0.41–0.60). The time-dependent Cox model revealed an overall adjusted HR for
mortality of 0.30 (95% CI 0.26–0.35) after counting vaccination for multi-years.
Conclusions: ESRD patients with HD receiving the influenza vaccination could have reduced risks of pneumonia/influenza
and other morbidities, ICU stay, hospitalization and death, particularly for the elderly.
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Introduction
The influenza virus is a common transmissible human
respiratory virus that causes significant morbidity and mortality.
In the Unites States, influenza can cause hospitalizations of more
than 225,000 patients and 36,000 deaths annually [1,2]. The
morbidity and mortality of influenza are increased in people of old
ages, immunocompromised patients, and those with chronic
diseases [3]. Patients with end-stage renal disease (ESRD) are
also at increased risk of influenza complications [4]. Infection is
the second leading cause of mortality and a major cause of
morbidity in ESRD patients [5]. In addition, mortality rate related
to pulmonary infection is likely 10-fold higher in ESRD patients
than in the general population [6]. Immune dysfunction, older
age, and comorbid conditions, such as diabetes mellitus, malnu-
trition, invasive dialysis procedures, disruption of skin and mucosa
barriers, and nosocomial transmission, contribute to the high
infection risk for ESRD patients [4,7]. The causes of immune
dysfunction in ESRD patients include diminished functions in
complement activation, neutrophil, monocyte/macrophage, T-
cell, and B-cell [8].
Observation studies have reported that influenza vaccination
can reduce the risk of deaths and hospitalizations among elderly
and high-risk populations [9,10]. Thus, annual influenza vaccina-
tion for ESRD patients is recommended [11]. However, little is
known on the effectiveness of influenza vaccine in ESRD patients.
Observation studies showed conflicting results.[12,13,14,15,16]
The present study aims to investigate the effectiveness of influenza
vaccination in reducing morbidity and mortality for ESRD
patients receiving hemodialysis (HD) using population-based
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universal insurance data, derived from the Taiwan National
Health Insurance (NHI) program.
Materials and Methods
Data Sources
The Taiwan NHI was integrated from 13 insurance programs
in 1995 in Taiwan. This insurance program has covered
approximately 99% of the entire 23.74 million people in Taiwan
since 1999 [17]. The Taiwan Bureau of National Health
Insurance had authorized the National Health Research Institutes
(NHRI) to manage reimbursement claims from hospitals and
clinics. A committee at the Bureau of National Health Insurance
was responsible to randomly select claims and to check the
accuracy of claims. NHRI also had been authorized to established
data sets for administrative and research uses. We obtained a sub-
dataset with one million of population from NHRI for this study.
This subset data is similar to the whole population in the
distributions in gender and age. The claims data included
information on demographic status, date and source of diagnosis,
ambulatory care, outpatient and inpatient treatment, dental
services, and physicians providing services. Claims data were
randomly audited by the insurance system. Data files are linked
with scrambled patient identification number to protect the
privacy of the patients. The International Classification of Disease,
9th Revision, Clinical Modification (ICD-9-CM) was used to
identify individual health status. This study was approved by the
Institutional Review Board of China Medical University.
Study Subjects
We identified patients with ESRD newly diagnosed in 1998–
2009 yearly from the sub-dataset with one million insured people.
The patients who had completed the seasonal influenza vaccina-
tion (ICD-9-CM V04.7 and V04.8) were designated in the vaccine
cohort, with the date of vaccination defined as the index date for
measuring the follow-up period. The patients who received
pneumococcal vaccine were excluded (N= 75). Newly diagnosed
HD patients without both influenza and pneumococcal vaccina-
tions were also identified annually as the non-vaccine cohort. The
corresponding non-vaccine cohort was selected randomly from the
same month of the index year.
Outcome Measures
Both cohorts were followed up since the index date for one year
or until selected events, death, or withdrawal from the insurance.
We were interested in outcome events of total hospitalization,
pneumonia or influenza (ICD-9-CM codes 480-487), hospitaliza-
tion for septicemia, bacteremia, or viremia (ICD-9-CM codes
038.x, 790.7, and 790.8), hospitalization for heart disease (ICD-9-
CM codes 401–429), respiratory failure (ICD-9-M codes 518.81,
518.82, 518.83, 518.84, 799.1), or intensive care unit (ICU)
admission or death. The history of coronary artery disease (ICD-9-
CM codes 410–413, 414.01–414.05, 414.8, and 414.9), congestive
heart failure (ICD-9-CM codes 428, 398.91, 402.x1), cancer (ICD-
9-CM codes 140–149, 150–159, 160–165, 170–175, 179–189,
190–199, 200, 202, 203, 210–213, 215– 229, 235–239, 654.1,
654.10, 654.11, 654.12, 654.13, 654.14), hyperlipidemia (ICD-9-
CM codes 272), hypertension (ICD-9-CM codes 401–405),
diabetes (ICD-9-CM codes 250), atrial fibrillation (ICD-9-CM
codes 427.31), stroke (ICD-9-CM codes 430–438), chronic
hepatitis (ICD-9-CM codes 571, 572.2, 572.3, 572.8, 573.1,
573.2, 573.3, 573.8, 573.9), and chronic obstructive pulmonary
disease (ICD-9-CM codes490, 491– 495, 496) were identified as
comorbidities before the index date.
Statistical Analysis
Proportion of annual influenza vaccination in HD patients was
measured chronologically from 1998–2009. Demographic char-
acteristics of HD patients and prevalence of comorbidities were
compared between the vaccine and non-vaccine cohorts, and
tested using Chi-square test for categorical variables and t-test for
continuous variables. Incidence rates for hospitalization events,
infections (pneumonia/influenza, septicemia, bacteremia and
viremia), heart disease, respiratory failure, intensive care unit
(ICU) admission, and mortality were estimated for each cohort.
The vaccine to non-vaccine cohort incidence rate ratio (IRR) and
95% confidence interval (CI) were estimated using Poisson
regression. Cox proportional hazards regression model was also
used to estimate the hazard ratio (HR) for each of these events and
the corresponding 95% CI, within one year after the vaccination.
The Cox proportional hazards regression model were also used to
estimate pneumonia/influenza-free rates, controlling for age, sex,
hyperlipidemia, hypertension, congestive heart failure, chronic
hepatitis, chronic obstructive pulmonary disease and calendar
year. Similarly, the probability free of respiratory failure, ICU
admission, and mortality were plotted using the Cox proportional
hazards regression model. The influenza vaccination changed
annually, we used the time-dependent Cox model to further
evaluate the mortality risk related to the vaccination for multiple
years. SAS version 9.1 (SAS Institute, Cary, NC, USA) was used
for data analyses; p ,0.05 was considered to indicate statistical
significance.
Results
From 1998 to 2009, new patients receiving HD increased
annually from 264 cases in 1998 to a peak of 368 cases in 2007,
and then declined to 347 cases in 2009 (Table 1). The proportion
of patients receiving influenza vaccine increased from 1.14% to a
peak of 38.0% in 2009. A total of 29 patients received both
seasonal influenza and influenza A (H1N1) vaccines in 2009. A
total of 103 patients received seasonal influenza vaccination only
(data not shown). Overall, 831 patients were in the influenza
vaccine cohort, which comprised less portion of women than 3187
patients in the non-vaccine comparison cohort (Table 2). The
Table 1. Proportion of annual influenza vaccination in
hemodialysis patients.
Influenza vaccine
Year N Yes No Proportion (%)
1998 264 3 261 1.14
1999 270 16 254 5.93
2000 313 50 263 15.97
2001 315 48 267 15.24
2002 335 80 255 23.88
2003 361 90 271 24.93
2004 363 78 285 21.49
2005 397 89 308 22.42
2006 355 90 265 25.35
2007 368 70 298 19.02
2008 330 85 245 25.76
2009 347 132 215 38.04
doi:10.1371/journal.pone.0058317.t001
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vaccine cohort mainly included the elderly, with the mean age
much higher than that of the non-vaccine cohort (70.26 9.96 vs.
59.4614.5 years). The vaccine cohort also tended to be more
prevalent with comorbidities. There was no patient who received
transplantation or was shifted to peritoneal dialysis during the
follow-up period.
The analysis for age-specific hospitalization shows that most of
patients hospitalized were the elderly (§ 65 years) (Table 3). The
overall crude hospitalization rate was 11.0% higher in the vaccine
cohort than in the non-vaccine cohort (99.4 vs. 89.4 per 100
person-years). However, the vaccine cohort had an adjusted HR of
0.81(95% CI=0.72–0.90) after controlling for sex, age, coronary
artery disease; congestive heart failure; chronic obstructive
pulmonary disease, cancer, stroke, and calendar year. The elderly
with vaccination had significant lower rate than those without
(100.8 vs. 133.9 per 100 person-years), with an adjusted IRR of
0.73 (95% CI 0.64–0.82).
Table 4 shows that the incidence of heart disease, the major
cause of hospitalization, was higher in the vaccine cohort than in
the non-vaccine cohort (65.3 vs. 51.7 per 100 person-years).
However, the adjusted HR of the vaccine cohort was 0.85 (95%
CI 0.75–0.96). The incidence rates of pneumonia/influenza,
hospitalization for septicemia/bacteremia/viremia, and respirato-
ry failure were also higher in the vaccine cohort than in the non-
vaccine cohort. However, adjusted HRs also demonstrated
protective association from the vaccination. Compared with the
patients in the non-vaccine cohort, those in the vaccine cohort
were less likely to be admitted in the ICU [2.6 vs. 6.8 per 100
person-years; adjusted HR 0.2 (95% CI 0.12–0.33)] and to be
deceased [18.5 vs. 21.0 per 100 person-years; adjusted HR 0.50
(95% CI 0.41–0.60)].
The evaluation for only the elderly also showed that those with
vaccination were at lower risks of pneumonia/influenza, hospital-
ization for septicemia/bacteremia/viremia, and heart disease,
ICU admission, respiratory failure, and death (data not shown).
The time-dependent Cox model revealed that the overall adjusted
HR for mortality associated with the vaccination reduced to 0.30
(95% CI 0.26–0.35), compared with non-vaccinated persons
(Table 5).
Figures 1A trough ID show that, compared with the non-
vaccine cohort, the vaccine cohort had significantly lower rates of
pneumonia/influenza (P-value= 0.02) (Figure 1A), respiratory
failure (P-value ,0.0001) (Figure 1B), ICU stay (Figure 1C) (P-
value ,0.0001), and mortality (Figure 1D) (P-value ,0.0001).
Discussion
Our study demonstrated that influenza vaccination for ESRD
patients receiving HD was associated with lower morbidities,
including total hospitalization, ICU admission, pneumonia/
influenza, septicemia/bacteremia/viremia, respiratory failure,
and heart disease. In addition, influenza vaccination was also
associated with lower all-cause mortality risk for 50%. The
mortality risk decreased further to have an overall adjusted HR of
0.30 as subjects with vaccinations for multiple years were counted.
Consistent with the present study, a previous research in the US
reported that the risks of hospitalization and death for HD patients
vaccinated against influenza are lower than those of unvaccinated
patients, with odds ratios of 0.93 (95% 0.90–0.95) and 0.77 (0.73–
Table 2. Demographic status and comorbidity at baseline in
hemodialysis patients with and without influenza vaccination.
Influenza vaccine p-value
Yes (n =831) No (n =3187)
Age, mean 6 SD 70.269.96 59.4614.5 ,0.0001#
Stratify age
18–39 8(0.96) 284(8.91) ,0.0001
40–64 127(15.3) 1714(53.8)
65+ 696(83.8) 1189(37.3)
Gender
Women 413(49.7) 1635(51.3) 0.41
Men 418(50.3) 1552(48.7)
Comorbidity
CAD 401(48.3) 997(31.3) ,0.0001
CHF 253(30.5) 672(21.1) ,0.0001
Cancer 82(9.87) 236(7.41) 0.02
Hyperlipidemia 466(56.1) 1342(42.1) ,0.0001
Hypertension 776(93.4) 2795(87.7) ,0.0001
Diabetes 552(66.4) 1694(53.2) ,0.0001
Atrial fibrillation 26(3.13) 67(2.10) 0.08
Chronic hepatitis 323(38.9) 874(27.4) ,0.0001
COPD 356(42.8) 917(28.8) ,0.0001
Abbreviations: CAD, coronary artery disease; CHF, congestive heart failure;
COPD; chronic obstructive pulmonary disease
Chi-square test; #: Two-sample t-test
doi:10.1371/journal.pone.0058317.t002
Table 3. Comparison in hospitalization rates between hemodialysis patients with and without influenza vaccination.
Vaccine Non-vaccine
Outcome Event PY Rate# Event PY Rate# IRR*(95% CI) Adjusted IRR(95% CI) Adjusted HR (95% CI)
Total Hospitalization 459 462 99.4 1688 1888 89.4 1.11(0.96, 1.28) 0.80(0.69, 0.94) 0.82(0.73, 0.91)
Age, years
18–39 1 5 20 113 205 55.1 0.40(0.03, 5.54) 0.36(0.03, 4.76) 0.36(0.05, 2.62)
40–64 59 62 95.2 820 1118 73.3 1.31(0.92, 1.86) 1.22(0.86, 1.74) 1.16(0.89, 1.52)
65+ 399 396 100.8 755 564 133.9 0.75(0.64, 0.89) 0.70(0.59, 0.82) 0.73(0.64, 0.82)
Rate#, incidence rate, per 100 person-years; IRR*, incidence rate ratio;
HR, hazard ratio adjusted for sex, age, coronary artery disease; congestive heart failure; chronic obstructive pulmonary disease, cancer, stroke, and calendar year
doi:10.1371/journal.pone.0058317.t003
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0.81), respectively [14]. Moreover, they found that vaccination was
significantly associated with lower risks of cause-specific mortality,
including cardiac and infectious deaths. Recent reports demon-
strated that influenza vaccination was associated with a lower
mortality risk [12,13]. The mortality hazard was reduced further
for patients receiving both pneumococcal and influenza vaccina-
tions. On the contrary, McGrath et al. recently reported little
clinical benefits of influenza vaccination on preventing hospital-
ization and death [16]. However, their study did not consider the
confounding effect of pneumococcal vaccination. Therefore, our
study observed closely the effectiveness of influenza vaccination, by
excluding the effect of pneumococcal vaccine. In addition, these
studies analyzed prevalent ESRD patients. Length of time with
ESRD may have confounding effect on the outcomes.
Compared with healthy control subjects, ESRD patients possess
suboptimal immune response rates but develop satisfying protec-
tion rates to influenza vaccination [18,19,20,21,22]. The antibody
response rates to influenza vaccination (defined as a four-fold
increase in hemagglutination inhibition titers) vary from 7% to
89% [18,19,20,21,22]. The seroprotection rates (defined as
hemagglutination inhibition titers$40) range from 46% to 93%,
depending on the specific strain measured [18,19,20,21,22].
Booster vaccination fails to improve the immune response
[20,21,23]. Influenza vaccination is safe without causing major
adverse effects in HD patients [20,23], and the number of minor
adverse reactions is low [20].
Since 1998, the Taiwan NHI program has started to offer
influenza vaccinations to high-risk subjects, including ESRD
patients and the elderly subjects. Majority of the vaccinated
subjects receive this service annually between October 1 and
December 31. However, the influenza vaccination rate in this
study was low for incident HD patients, especially in the beginning
years (1998 and 1999). The higher vaccination rate in 2009 was
likely due to the pandemic novel influenza A (H1N1) in April 2009
[24]. The low vaccination rate may be attributed to the lack of
awareness on its benefit, fear of adverse reactions, and lack of
physician recommendation [25]. The goal of the World Health
Organization is to increase the annual influenza vaccination rate
to 90% by 2010 for ESRD patients.
Influenza may lead to viral pneumonia and bacterial superin-
fection. HD patients are susceptible to pulmonary infection.
Transient hypoxemia occurs during dialysis because of leukocyte
migration in the pulmonary vasculature and loss of carbon dioxide
[6]. In addition, HD patients are exposed to other patients and
medical staff. Our study demonstrated that influenza vaccination
was associated with a lower risk of pneumonia/influenza during
the first 3 months after vaccination (data not shown). Seroprotec-
tion was maintained at least for 3 months and up to 6 months after
influenza vaccination in patients with renal diseases [26].
Consistent with the findings of the present study, Gilbertson
reported that influenza vaccination is associated with a lower risk
of heart disease in ESRD patients [14]. For patients with chronic
kidney disease, an association between influenza vaccination and
atherosclerotic heart disease event rates also exists [27]. Systemic
inflammation caused by influenza infection may lead to endothe-
lial injury, impaired vasodilatation, and enhanced thrombosis
formation [28]. Inflammation is highly associated with increasing
cardiovascular mortality [29,30].
The current study has several limitations. First, the NHI
database provided limited information on socio-demographic
characteristics, with unavailable information on marital status,
educational level, smoking habit, body-mass index, and laboratory
Table 4. Hospitalization, intensive care unit utilization, and mortality comparison between hemodialysis patients with and without
influenza vaccination.
Vaccine Non-vaccine
Outcome Event PY Rate# Event PY Rate# IRR
*(95% CI)
Adjusted IRR (95%
CI)
Adjusted HR (95%
CI)
Pneumonia/influenza{ 139 620 22.4 445 2584 17.2 1.30(1.08, 1.56) 0.77(0.64, 0.93) 0.78(0.64, 0.96)
Septicemia, bacteremia, and
viremia{
103 637 16.2 347 2661 13.0 1.24(1.02, 1.50) 0.66(0.47, 0.92) 0.72(0.56, 0.88)
Heart disease{ 341 522 65.3 1138 2203 51.7 1.26(1.08, 1.47) 0.83(0.71, 0.97) 0.85(0.75, 0.96)
Respiratory Failure{ 66 653 10.1 262 2697 9.7 1.04(0.84, 1.29) 0.52(0.42, 0.64) 0.53(0.41, 0.70)
Intensive care unit admission{ 17 660 2.6 184 2696 6.8 0.38(0.27, 0.53) 0.19(0.14, 0.27) 0.20(0.12, 0.33)
Mortality{ 123 665 18.5 581 2765 21.0 0.88(0.73, 1.07) 0.49(0.41, 0.59) 0.50(0.41, 0.60)
Rate#, incidence rate, per 100 person-years; IRR*, incidence rate ratio
Hospitalization{: adjusted for age, CAD, CHF, cancer, COPD, stroke, and calendar year
Hospitalization for pneumonia/influenza{: adjusted for age, sex, CAD, CHF, cancer, diabetes, atrial fibrillation, COPD, and calendar year
Hospitalization for septicemia, bacteremia, and viremia{: adjusted for age, cancer, diabetes, atrial fibrillation, and calendar year
Hospitalization for heart disease{: adjusted for age, CAD, CHF, hypertension, diabetes, atrial fibrillation, chronic hepatitis, and calendar year
Respiratory Failure{: adjusted for age, sex, CAD, cancer, CHF, diabetes, hypertension, chronic hepatitis, and calendar year
Intensive care unit{: adjusted for age, cancer, hyperlipidemia, hypertension, diabetes, atrial fibrillation, chronic hepatitis, and calendar year
Mortality{: adjusted for age, sex, CAD, cancer, CHF, diabetes, hyperlipidemia, hypertension, chronic hepatitis, atrial fibrillation, COPD, and calendar year
doi:10.1371/journal.pone.0058317.t004
Table 5. Time-dependent Cox model estimated hazard ratios
and 95% confidence intervals of mortality risk associated with
the vaccination.
Hazard ratio(95% CI)
Crude Adjusted{
Vaccination 0.47(0.41, 0.55) 0.30(0.26, 0.35)
Adjusted HRs{: adjusted for age, sex, CHF, diabetes, hyperlipidemia,
hypertension, chronic hepatitis, and atrial fibrillation
doi:10.1371/journal.pone.0058317.t005
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data, such as hemoglobin, albumin, and residual renal function.
These variables cannot be adjusted in the analysis. Furthermore,
certain information on chronic conditions, such as hyperlipidemia
and hypertension, were not available for some individuals.
However, HD patients were visited by health care professionals
frequently, the claim data were reliable. Moreover, the decision to
receive vaccination may have been affected by socioeconomic
status, as well as availability of health care and medical providers.
Although multivariate analysis was used, selection bias may occur.
Fourth, this study focused only on all-cause mortality because the
cause of death cannot be obtained from the database. Finally, the
strain and virulence of the predominant virus and the match
between the circulating virus strain and the virus strain selected in
the vaccine varied from year to year. Therefore, we adjusted the
calendar year for temporal effect.
Conclusions
Our study provides evidence that influenza vaccination is
associated with the reduction of mortality and morbidity in HD
patients. Thus, HD patients should be vaccinated annually. More
large-scale prospective studies are necessary to analyze the issue.
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Figure 1. The probability free of pneumonia/influenza, respiratory failure, intensive care unit stay, and mortality for hemodialysis
patients with (dashed line) or without (solid line) influenza vaccination.
doi:10.1371/journal.pone.0058317.g001
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